Core Viewpoint - The article highlights the successful mass production of medical-grade alpha isotopes by the China Spallation Neutron Source, which will accelerate the clinical application of domestically produced alpha nuclear medicines in China [1] Group 1: Alpha Isotope Production - The China Spallation Neutron Source has achieved the first-ever mass production of medical-grade alpha isotopes at curie level, marking a significant advancement in the field [1] - The production of alpha isotopes like actinium-225 and radium-223 has been a global challenge due to multiple technical barriers, which has historically limited the development of China's alpha nuclear medicine industry [1] Group 2: Clinical Applications - Alpha isotopes are known for their "high energy and short range" properties, allowing for precise targeting of cancer cells while minimizing damage to surrounding healthy tissues, making them valuable in tumor treatment [1] - Radium-223 has been approved for clinical treatment of bone metastatic castration-resistant prostate cancer, while actinium-225 and lead-212 (bismuth-212) show significant efficacy in targeted therapies for advanced prostate cancer and neuroendocrine tumors [1] - The mass production of domestically sourced isotopes will provide stable support for related clinical research and applications in China [1]

Group 1 - The core announcement is that Yantai Dongcheng Pharmaceutical Group Co., Ltd.'s subsidiary, Yantai Lanacheng Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of the drug 177Lu-LNC1009 injection, which targets advanced malignant solid tumors [1][2] - The drug 177Lu-LNC1009 is a dual-target radioactive therapy aimed at FAP-positive and integrin αvβ3-positive patients, showing potential for improved tumor targeting and treatment efficacy [2][3] - The total research and development investment for 177Lu-LNC1009 has reached approximately 13.579 million yuan [2] Group 2 - The company announced that its full subsidiary, Nanjing Jiangyuan Andico Positron Research and Development Co., Ltd., has had its product, Technetium-99m (99mTc) Tetrofosmin injection, included in the National Medical Insurance Directory for 2025, which is expected to enhance market accessibility and promote sales [4] - The inclusion in the medical insurance directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's financial performance in the short term [4]

Core Viewpoint - The article discusses the discovery of novel micropeptides in human gastric cancer tissues, highlighting their potential as therapeutic targets and the role of artificial intelligence in their functional annotation [2][5]. Group 1: Discovery of Micropeptides - A research team from Zhejiang University identified nearly ten thousand novel micropeptides in human gastric cancer tissues, suggesting that these previously underexplored proteins may hold keys to treating various diseases, including cancer [2]. - The study challenges the traditional binary classification of coding and non-coding genes, showcasing the significant potential of the non-canonical proteome in cancer biology research [3]. Group 2: Functional Characterization of Micropeptides - The team focused on liver cancer-related micropeptides, revealing that a specific micropeptide, MRPIP, regulates mitochondrial RNA processing and energy metabolism, thereby inhibiting liver cancer proliferation [5][12]. - MRPIP was found to be significantly downregulated in liver cancer tissues and associated with poor prognosis, indicating its potential as a biomarker [9]. Group 3: Mechanistic Insights - The research demonstrated that MRPIP interacts with the mitochondrial RNA processing complex, disrupting its assembly and affecting mitochondrial RNA processing and protein translation, which ultimately suppresses tumor growth [12]. - The transcription factor FOXO1 was shown to upregulate MRPIP under glucose starvation conditions, linking energy stress responses to mitochondrial translation regulation [12]. Group 4: Development of Therapeutic Candidates - Based on the functional insights of MRPIP, the team synthesized a 20-amino acid micropeptide drug precursor, PMHR, which effectively inhibits liver cancer progression by targeting mitochondrial translation and energy metabolism [13]. - The study provides a new strategy for developing targeted therapies based on endogenous bioactive small molecules [15]. Group 5: Data Accessibility and Future Research - The identified micropeptides and related data are included in the Human Micropeptide Atlas (HMPA), a visual dataset that integrates clinical data and micropeptide information from various cancers, facilitating further research in precision medicine [16].